Last reviewed · How we verify

Cefazolin and indomethacin

Thomas Jefferson University · FDA-approved active Small molecule

Cefazolin and indomethacin is a Beta-lactam antibiotic + NSAID combination Small molecule drug developed by Thomas Jefferson University. It is currently FDA-approved for Surgical site infection prophylaxis and perioperative pain/inflammation management.

This combination uses cefazolin (a beta-lactam antibiotic) to inhibit bacterial cell wall synthesis and indomethacin (an NSAID) to reduce inflammation and inhibit prostaglandin synthesis.

This combination uses cefazolin (a beta-lactam antibiotic) to inhibit bacterial cell wall synthesis and indomethacin (an NSAID) to reduce inflammation and inhibit prostaglandin synthesis. Used for Surgical site infection prophylaxis and perioperative pain/inflammation management.

At a glance

Generic nameCefazolin and indomethacin
SponsorThomas Jefferson University
Drug classBeta-lactam antibiotic + NSAID combination
TargetBacterial penicillin-binding proteins (cefazolin); COX-1 and COX-2 (indomethacin)
ModalitySmall molecule
Therapeutic areaInfectious Disease / Perioperative Medicine
PhaseFDA-approved

Mechanism of action

Cefazolin is a first-generation cephalosporin that binds to penicillin-binding proteins and disrupts bacterial cell wall cross-linking, leading to cell lysis and death. Indomethacin is a non-selective cyclooxygenase (COX) inhibitor that reduces prostaglandin production, thereby decreasing inflammation, pain, and fever. This combination is typically used perioperatively to provide both antimicrobial coverage and anti-inflammatory/analgesic effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cefazolin and indomethacin

What is Cefazolin and indomethacin?

Cefazolin and indomethacin is a Beta-lactam antibiotic + NSAID combination drug developed by Thomas Jefferson University, indicated for Surgical site infection prophylaxis and perioperative pain/inflammation management.

How does Cefazolin and indomethacin work?

This combination uses cefazolin (a beta-lactam antibiotic) to inhibit bacterial cell wall synthesis and indomethacin (an NSAID) to reduce inflammation and inhibit prostaglandin synthesis.

What is Cefazolin and indomethacin used for?

Cefazolin and indomethacin is indicated for Surgical site infection prophylaxis and perioperative pain/inflammation management.

Who makes Cefazolin and indomethacin?

Cefazolin and indomethacin is developed and marketed by Thomas Jefferson University (see full Thomas Jefferson University pipeline at /company/thomas-jefferson-university).

What drug class is Cefazolin and indomethacin in?

Cefazolin and indomethacin belongs to the Beta-lactam antibiotic + NSAID combination class. See all Beta-lactam antibiotic + NSAID combination drugs at /class/beta-lactam-antibiotic-nsaid-combination.

What development phase is Cefazolin and indomethacin in?

Cefazolin and indomethacin is FDA-approved (marketed).

What are the side effects of Cefazolin and indomethacin?

Common side effects of Cefazolin and indomethacin include Hypersensitivity reactions (rash, anaphylaxis), Gastrointestinal upset (nausea, dyspepsia), Renal impairment, Bleeding risk (indomethacin).

What does Cefazolin and indomethacin target?

Cefazolin and indomethacin targets Bacterial penicillin-binding proteins (cefazolin); COX-1 and COX-2 (indomethacin) and is a Beta-lactam antibiotic + NSAID combination.

Related